X4 Pharmaceuticals Inc.

XFOR | NASDAQ

Price Alert Chart Builder DCF Calculator

$3.48

-$0.02 (-0.43%)

Sep 22, 2026, 11:06 AM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-0.43%

(1D)

Rating

Updated: Aug 22, 2026

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $328.7M

1D Range

3.48 3.56

52W Range

2.80 4.83

Valuation (TTM)

PE -2.92

PB 2.12

EV/EBITDA -1.54

Valuation (NTM)

Forward PE N/A

Forward PEG -0.37

Price Target $11.50

Cash Flow

FCF Yield -25.4%

SBC Adj. FCF Yield -28.0%

SBC Impact -10.2%

Margins

Gross Margin 81.2%

Operating Margin -554.7%

FCF Margin -528.4%

Growth (CAGR)

Revenue 3Y | 5Y 46.6% | 65.5%

Dil EPS 3Y | 5Y -41.6% | 73.7%

FCF 3Y | 5Y 14.1% | -5.3%

Returns

ROA -35.6%

ROE -63.0%

ROIC -37.5%

Financial Health

Net Cash

$207.5M

Current Ratio 11.30

Interest Coverage -10.06

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

X4 Pharmaceuticals, Inc. is a biopharmaceutical firm committed to the discovery, development, and commercialization of innovative therapies for uncommon immune system disorders. Its primary drug candi...

Sector Healthcare

Industry Biotechnology

Employees 45

IPO Date Nov 15, 2017

Website www.x4pharma.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 4, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$11.50

Upside

+230.46%

Buy (2)

Hold (0)

Sell (0)

Analyst Details ➞